A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Multidrug-resistant fungal pathogens pose a significant threat to public health. Some Candida pathogens contribute to over one billion infections and approximately 1.5 million human deaths globally each year. Among these, the well- characterized C. albicans causes systemic infections with mortality rates of up to 72%, and is increasingly resistant to current antifungal drugs. Advancing our understanding of fungal molecular biology and gene-function relationships in Candida species is essential to elucidate the molecular mechanisms of antifungal resistance and inform strategies for combating multidrug-resistant fungi. However, the relationships between genes and functions conferring fungal robustness, including multidrug-resistant phenotypes, are complex and remain largely unexplored in Candida species, even in C. albicans, where approximately one-third of the proteome has only been annotated through comparative genomics. Functional genomics approaches such as gene knockout libraries via transposon mutagenesis and homologous recombination, have been developed for C. albicans over several decades, but these methods offer limited genome coverage. Major obstacles include complex polyploid genomes, low transformation efficiency, absence of autonomously replicating plasmids, and the need for multiplexed genome editing to dissect traits governed by multiple cellular processes. The goal of this exploratory project is to overcome key limitations in high-throughput functional genomics by developing tools for efficient DNA transformation and CRISPR-based genome editing in C. albicans, and applying these tools to perform genome-wide CRISPR screening to identify genes and cellular processes critical for antifungal resistance. This work builds on our recent progress in developing synthetic biology tools for diploid C. albicans, which may be extended to other Candida species. We improved chemical transformation efficiency by over two orders of magnitude, from 102 to 104 cfu/g DNA, by modulating cell stress tolerance. We also developed synthetic guide RNAs (gRNAs) with integrated repair templates, referred to as CRISPR- GRIT, which comprise tRNA, repair template, seed sequence, and scaffold, enabling precise, multiplexable genome editing without the need for large donor templates. To achieve our goal, we propose two exploratory aims. Aim 1 will develop foundational synthetic biology toolboxes for high-throughput, genome-wide functional genomics in diploid C. albicans. We will engineer autonomously replicating linear plasmids, coupled with a modular CRISPR-GRIT design, for precise genome editing. In addition, we will systematically characterize environmental variables (e.g., chemical, pH, temperature) and genetic variables (e.g., replicating plasmids) to optimize transformation conditions and achieve >106 cfu/g, a critical threshold for genome-wide CRISPR screening. Aim 2 will construct a pooled CRISPR library targeting all genes in C. albicans and initiate screening to identify genetic determinants of antifungal resistance. This high-risk, high-reward project will develop innovative synthetic biology tools for high-throughput functional genomics in difficult- to-manipulate fungi, advancing our fundamental knowledge of gene functions and biological processes underlying important phenotypes such as antifungal resistance, and laying the foundation for antifungal therapeutic development.
Grant Summary
A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $230K for university, nonprofit, healthcare org. Applications are due 2028-07-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $230K
2028-07-31
- 1Confirm your organization is eligible for A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance: Frequently Asked Questions
Who is eligible for the A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance?
A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance provide?
A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance provides up to $230K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance deadline?
Applications for A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance are due 2028-07-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance?
To apply for A Genome-Wide CRISPR Screening Platform in Diploid Candida Albicans to Uncover Mechanisms of Antifungal Resistance, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.